# A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

> **NCT07555483** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Grifols Therapeutics LLC** · enrollment: 40 (estimated)

## Conditions studied

- Alpha 1 Antitrypsin Deficiency

## Interventions

- **DRUG:** Alpha-1 15%
- **OTHER:** Liquid Alpha1-PI

## Key facts

- **NCT ID:** NCT07555483
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2026-09-29
- **Final completion:** 2026-09-29
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07555483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07555483, "A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07555483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*